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Abstract
Nontuberculous mycobacteria (NTM) that cannot be identiﬁed to the species level by reverse line blot hybridization assays and sequencing
of the 16S rRNA gene comprise a challenge for reference laboratories. However, the number of 16S rRNA gene sequences added to
online public databases is growing rapidly, as is the number of Mycobacterium species. Therefore, we re-analysed 178 Mycobacterium isolates
with 53 previously unmatched 16S rRNA gene sequences, submitted to our national reference laboratory in 1999–2007. All sequences
were again compared with the GenBank database sequences and the isolates were re-identiﬁed using two commercially available identiﬁca-
tion kits, targeting separate genetic loci. Ninety-three out of 178 isolates (52%) with 20 different 16S rRNA gene sequences could be
assigned to validly published species. The two reverse line blot assays provided false identiﬁcations for three recently described species
and 22 discrepancies were recorded in the identiﬁcation results between the two reverse line blot assays. Identiﬁcation by reverse line blot
assays underestimates the genetic heterogeneity among NTM. This heterogeneity can be clinically relevant because particular sub-group-
ings of species can cause speciﬁc disease types. Therefore, sequence-based identiﬁcation is preferable, at least at the reference laboratory
level, although the exact targets needed for clinically useful results remain to be established. The number of NTM species in the environ-
ment is probably so high that unidentiﬁable clinical isolates should be given a separate species status only if this is clinically meaningful.
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Introduction
The isolation frequency of nontuberculous mycobacteria
(NTM) increases in many countries where the incidence of
tuberculosis is in decline [1,2]. The NTM are ubiquitous in
the environment and their presence in clinical samples does
not necessarily indicate NTM disease. Assessment of the
clinical relevance of these isolates is not straightforward; the
American Thoracic Society has published diagnostic criteria
to aid in this assessment [3].
Clinical relevance differs signiﬁcantly depending upon the
NTM species, which makes species identiﬁcation crucial [3].
Currently, NTM are mostly identiﬁed using molecular tools,
such as species-speciﬁc probes, which are often incorporated
in commercial line probe assays, or the direct sequencing of
semi-conserved genes with proven taxonomic value. Among
these, the 16S rRNA, rpoB and hsp65 genes and the16S-23S
internal transcribed spacer region are most commonly used
[4–7]. However, not all clinical NTM isolates can be convinc-
ingly identiﬁed by molecular identiﬁcation. The ongoing
increase in the number of newly recognized species is testi-
mony to this phenomenon [8].
To establish the magnitude of the problem of unidentiﬁable
NTM, we re-investigated all NTM submitted to the national
reference laboratory in the Netherlands in 1999–2007 that
could previously not be convincingly identiﬁed by partial
16S rRNA gene sequencing. All sequences were re-analysed
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and the isolates re-identiﬁed applying two commercially avail-
able identiﬁcation kits that target two separate genetic loci.
Materials and Methods
At the national mycobacteria reference laboratory (National
Institute for Public Health and the Environment; RIVM) in
the Netherlands, NTM are identiﬁed using the Inno-Lipa
Mycobacteria v2 (Innogenetics, Ghent, Belgium) reverse line
blot assay, in accordance with the manufacturer’s instruc-
tions. If no identiﬁcation to the species level is obtained,
additional sequencing of the hypervariable region A (151 bp)
of the 16S rRNA gene is performed, but only upon request
by the referring clinician. Prior to 2004, we used the Accu-
Probe (GenProbe, San Diego, CA, USA) assay as a ﬁrst line
of NTM identiﬁcation.
If the 16S rRNA sequences yielded no full match with
GenBank (National Center for Biotechnology Information,
NCBI; http://www.ncbi.nlm.nih.gov) sequences or a match
with that of a species not validly published at the time, the
respective isolates were designated ‘Unknown Mycobacterium
species (UMS)’ and numbered consecutively. We extracted
these sequences from our database and subjected them to a
new comparison with the GenBank sequences in June 2008.
To assess the impact of reverse line blot assays on the
disclosure of genetic diversity among NTM, at least one iso-
late from each UMS was subjected to additional identiﬁcation
using the GenoType Mycobacterium CM/AS (Hain Life-
science, Nehren, Germany) and Inno-Lipa Mycobacteria v2
reverse line blot assays in accordance with the manufactur-
ers’ instructions.
In our re-analysis, we considered UMS with a > 1-bp
sequence difference from a species type strain, or with a
reverse line blot identiﬁcation conﬂicting with the 16S rRNA
gene sequence result, as being related to that species. UMS
with 16S rRNA gene sequences 1 bp divergent from that of
an established species were considered sequevars of that
species, unless the reverse line blot identiﬁcation results
were discordant. UMS with 16S rRNA gene sequences iden-
tical to that of a type strain of a species available in GenBank
and concordant reverse line blot results were considered to
be representative of that species.
Results
We found 178 clinical isolates with 53 different 16S rRNA
gene sequences not matching those of validly published
species available in the GenBank database at the time of
referral to the RIVM. These comprise 4% of the 4481
NTM isolates referred to the RIVM in the study period.
During this period, another 913 NTM isolates (20%) were
identiﬁed no further than Mycobacterium avium complex,
except M. avium or Mycobacterium intracellulare (n = 302),
Mycobacterium fortuitum complex (n = 104), NTM not
reacting with the M. avium complex and the Mycobacterium
tuberculosis complex AccuProbe kits (n = 347) or NTM
reacting only with the Mycobacterium species probe of the
Inno-Lipa assay (n = 70).
Identiﬁcation by 16S rRNA gene sequencing for these 913
isolates was not requested by the referring clinicians and
thus was not conducted.
The isolation frequency of the UMS and results of the
new identiﬁcation efforts are detailed in Table 1. Based on
our re-analysis of the partial 16S rRNA gene sequence, 20
UMS (yielding 93 isolates; 52%) could be assigned to validly
published species, including Mycobacterium noviomagense
(UMS1; Table 1), which we described recently [9]. The
remaining 85 isolates, comprising 33 UMS, were related to
the M. avium complex (n = 10), M. fortuitum complex (n = 7),
Mycobacterium xenopi (n = 3), Mycobacterium terrae complex
(n = 4), Mycobacterium gordonae (n = 3), Mycobacterium simiae
(n = 2), Mycobacterium interjectum (n = 2) or assigned to the
slow or rapid growers, distantly related to established spe-
cies (Table 1).
With the GenoType CM/AS assay, we identiﬁed 28 of the
53 UMS (53%) to species (n = 24) or complex level (M. fortu-
itum complex; n = 4). Twelve of these identiﬁcations were
not in accordance with species or complex identiﬁcations
based on the partial 16S rRNA gene sequence (Table 1).
With the Inno-Lipa assay, we identiﬁed 19 UMS (36%) to
species (n = 7) or complex levels (n = 12; six M. avium com-
plex, six M. fortuitum complex). Eight identiﬁcation results
were discordant with species or complex identiﬁcations
based on the partial 16S rRNA gene sequence (Table 1).
Identiﬁcations as M. fortuitum complex or M. gordonae with
the two assays are especially frequent.
Discordance between species or complex identiﬁcations
with the two hybridization assays was noted in six different
UMS (UMS 2, 10, 11, 13, 49 and 64; Table 1). This mainly
involved isolates related to the M. avium complex, M. interjec-
tum or Mycobacterium scrofulaceum.
Twenty-six (49%) of the UMS were only encountered once;
the average number of isolates per UMS was 3.4 (range 1–24).
Most UMS isolates were cultured from respiratory samples
(n = 162; 129 sputa, 33 broncho-alveolar lavage ﬂuid samples;
91%). Sixteen UMS isolates (9%) were cultured from normally
sterile samples, including bone marrow (n = 1), lung (n = 2),
lymph node (n = 4), pleura (n = 1) and joint biopsies (n = 1),
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as well as urine (n = 4), gastric aspirate (n = 2) and maxillary
sinus lavage ﬂuid (n = 1).
Discussion
Unidentiﬁable NTM are a signiﬁcant phenomenon, comprising
at least 4% of all NTM submitted to our national reference
laboratory. Even though their number was halved, to 2%, by
our re-analysis, this remains well above the 1% estimated by
Tortoli et al. [10]. However, we most likely underestimate the
number of UMS isolates. For isolates identiﬁed to genus or
complex level with the hybridization assays, additional 16S
rRNA gene sequencing is not free of charge and therefore not
routinely performed. Yet, this may reveal novel sequences and
thus UMS. In our situation, this appears to be most prominent
in isolates identiﬁed with hybridization assays as M. fortuitum
complex, M. avium complex or M. gordonae. In the 20% of all
submitted isolates that were not identiﬁed to species level,
many additional UMS may be identiﬁed.
TABLE 1. Identiﬁcation results of previously unidentiﬁable nontuberculous mycobacteria species
Unknown
Mycobacterium species n 16S hypervariable region A (GenBank)
Genotype
CM/AS Inno-Lipa Interpretation
1 18 100% Mycobacterium noviomagense NLA000500338T Myc Myc M. noviomagense [9]
2 2 99% Mycobacterium intracellulare W249st MSC MAIS MAC
3 2 100% Mycobacterium nonchromogenicum FI-06254 Myc Myc M. nonchromogenicum
7 9 100% Mycobacterium arupense DSM 44942 Myc Myc M. arupense
10 6 99% Mycobacterium colombiense CIP 108962 MINT MAIS MAC
11 3 99% Mycobacterium interjectum DSM 44064 MIJ MAIS M. interjectum sqv.
12 4 100% Mycobacterium saskatchewanense 00-250 MINT Myc M. saskatchewanense
13 4 100% Mycobacterium seoulense 03–19 MSC MAIS M. seoulense
14 1 96% Mycobacterium pyrenivorans DSM 44605 Myc Myc RGM
15 3 100% Mycobacterium pulveris CIP 106804 Myc Myc M. pulveris
16 5 98% M. saskatchewanense 00–250 MSC Myc MAC
17 2 99% Mycobacterium smegmatis ATCC 700504 MSM MSM M. smegmatis sqv
18 3 100% Mycobacterium holsaticum 1406 Myc MGO M. holsaticum
19 4 100% Mycobacterium hiberniae DSM 44241 Myc Myc M. hiberniae
20 2 95% M. nonchromogenicum ATCC 19530 Myc Myc M. terrae related sp.
22 4 98% Mycobacterium szulgai CIP 104532 Myc Myc SGM
23 6 99% Mycobacterium chlorophenolicum CIP 104189 Myc Myc RGM
24 9 99% Mycobacterium kumamotonense CCUG 51961 Myc Myc Mycobacterium terrae related sp.
25 2 98% Mycobacterium fallax ATCC 35219 MGO Myc RGM
26 4 95% Mycobacterium botniense DSM 44537 MFO2 Myc M. xenopi related sp.
27 24 100% Mycobacterium gordonae FI-06271 MGO MGO M. gordonae
28 5 100% Mycobacterium fortuitum ATCC 49403 MFO2 MFO M. fortuitum
29 1 96% Mycobacterium doricum DSM 44339 Myc MFO RGM
30 3 98% Mycobacterium mucogenicum ATCC 49650 MFO2 MFO M. fortuitum complex
31 1 100% Mycobacterium avium 104 MAV MAV M. avium
32 4 99% M. terrae ATCC 15755 Myc Myc M. terrae related sp.
33 4 99% Mycobacterium mucogenicum ATCC 49650 MMC Myc RGM
34 4 98% Mycobacterium gordonae CIP 104529 MGO MGO M. gordonae related sp.
35 1 100% Mycobacterium triviale ATCC 23290 Myc Myc M. triviale
36 1 98% Mycobacterium simiae CIP 104531 MLE Myc M. simiae related sp.
37 1 98% M. simiae CIP 104531 Myc MAIS M. simiae related sp.
38 4 100% Mycobacterium palustre DSM 44572 M. palustre Myc M. palustre
39 1 100% Mycobacterium lentiﬂavum CIP 105465 MLE Myc M. lentiﬂavum
40 1 99% Mycobacterium gordonae CIP 104529 MGO MGO M. gordonae sqv.
41 1 98% Mycobacterium asiaticum DSM 44297 MGO Myc M. gordonae related sp.
42 4 99% Mycobacterium holsaticum 1406 Myc Myc SGM
43 3 100% Mycobacterium branderi CIP 104592 Myc Myc M. branderi
44 2 100% Mycobacterium nebraskense DSM 44803 Myc MAIS M. nebraskense
45 2 100% Mycobacterium aurum N196 Myc Myc M. aurum
46 1 98% Mycobacterium avium ATCC 25291 MSC Myc MAC
48 2 94% Mycobacterium branderi CIP 104592 Myc Myc SGM
49 1 99% Mycobacterium scrofulaceum CIP 105416 MSC MINT1 MAC
50 1 100% Mycobacterium cosmeticum CIP 108169 MFO MFO M. cosmeticum
52 1 98% Mycobacterium sphagni DSM 44076 MPE MFO M. fortuitum complex
53 1 97% Mycobacterium doricum DSM 44339 Myc Myc RGM
54 3 99% Mycobacterium fortuitum ATCC 49404 MPE MFO M. fortuitum complex
59 2 99% Mycobacterium sphagni DSM 44076 MMC Myc M. fortuitum complex
60 1 94% Mycobacterium tusciae CIP 106367 Myc Myc RGM
61 1 100% M. ﬂorentium DSM 44852 Myc Myc M. ﬂorentinum
62 1 98% Mycobacterium porcinum CIP 105392 MMC Myc M. fortuitum complex
63 1 100% Mycobacterium monacense B9-21-178 Myc Myc M. monacense
64 1 99% Mycobacterium interjectum DSM 44064 MIJ Myc M. interjectum sqv.
65 1 98% Mycobacterium celatum CIP 106109 Myc Myc M. terrae related sp.
Myc, Mycobacterium species; MSC, M. scrofulaceum; MAIS, M. avium-intracellulare-scrofulaceum complex; MINT, M. intracellulare; MIJ, M. interjectum; MSM, M. smegmatis; MGO,
M. gordonae; MFO, M. fortuitum; MAV, M. avium; MPE, M. peregrinum; MMC, M. mucogenicum; MLE, M. lentiﬂavum; MAC, M. avium complex; RGM, rapid-growing Mycobacte-
rium; SGM, slow-growing Mycobacterium; sqv., sequevar; sp., species.
Bold indicates that identiﬁcation to species level was obtained after re-analysis of the 16S RNA gene sequence. Italics indicates identiﬁcation with hybridization assays not in
accordance with partial sequence results.
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By re-analysis of the 16S rRNA sequences, we identiﬁed
20 of our 53 UMS as validly published NTM species. Forty-
eight percent of the unidentiﬁable isolates (n = 85) represent
33 novel species or variants of established species. Many
UMS are genetically related to M. avium and M. fortuitum
complex members. This implies that, within these speciﬁc
complexes, more species exist than are currently described.
Referral to our reference laboratory may be more likely for
strains considered as possible pathogens and this creates a
potential selection bias.
Most of the UMS were single pulmonary isolates, which
may reﬂect limited clinical relevance (i.e. patients failed to
meet the American Thoracic Society diagnostic criteria
for pulmonary NTM disease) [3] or a reluctance to submit
further isolates for identiﬁcation. In nine cases, UMS were
isolated from normally sterile sites, and thus likely are causa-
tive agents of true NTM disease.
The current reverse line blot assays can only recognize a
limited number of species. For manufacturers, it is a matter
of choice to decide which species should be covered and
whether recently described species should be added or
replace species currently included in the assay. Many recently
described species (e.g. Mycobacterium monacense, Mycobacte-
rium ﬂorentinum; Table 1) are now identiﬁed as ‘Mycobacte-
rium species other than those incorporated in the
hybridization assay’. The results obtained in the present
study demonstrate that hybridization assays also provide
false identiﬁcations for some recently described species,
including Mycobacterium holsaticum, Mycobacterium cosmeticum
and Mycobacterium saskatchewanense (Table 1); users should
be aware of these two pitfalls, perhaps through a note in the
assay manuals.
Moreover, the hybridization assays are based on the detec-
tion of short DNA sequences. This monophasic approach pre-
cludes a high degree of genetic variation among identically
identiﬁed strains and thus misses the distinction between
related (sub)species. Importantly, we also recorded differences
in identiﬁcation results between the two hybridization assays
tested. Because clinical relevance and drug susceptibility of
NTM species differs, correct identiﬁcation is important [3,8–
11]. Sequence-based identiﬁcation is more reliable than the
limited approach of reverse line blot assays, although this
requires sophisticated and expensive laboratory equipment
and may be most suitable for reference laboratories.
For UMS, the 16S rRNA gene sequence similarity to that
of an established species does not provide guidance for clini-
cians. In our previous identiﬁcation of M. noviomagense, we
noted that close genetic relationships with M. xenopi were
associated with very different phenotypical features, drug
susceptibility and clinical relevance [9]. Genetic relationships,
based on a partial single target should, therefore, be inter-
preted with caution.
Identiﬁcation based on DNA sequence analysis of a (par-
tial) single gene disregards genetic variation in the rest of the
genome. Our use of the hypervariable region A of the 16S
rRNA gene only can be criticized because sequence variation
outside this region may alter the species designation. Multi-
gene identiﬁcation may further improve our understanding of
mycobacterial taxonomy and result in clinically relevant dis-
tinctions within species. Mycobacterium kansasii is a good
example in this respect because seven subtypes have been
described based on multiple genetic targets: one subtype
causes pulmonary disease, one is a causative agent of HIV-
related disseminated disease, whereas the ﬁve remaining
types are environmental bacteria, not associated with human
disease [12]. The maximum resolution of genetic identiﬁca-
tion will only be achieved after the introduction of routine
sequencing of whole genomes of all available Mycobacterium
isolates. This will lead to a robust phylogenetic tree that can
be enriched with clinical data as a self-learning model to
improve our understanding of mycobacterial virulence. It is
conceivable that this will also lead to a complete reconsider-
ation of the ever growing list of new species that are
described on the basis of limited variation of semi-conserved
genes and some degree of phenotypic variation.
It is questionable whether our UMS isolates with novel
partial 16S rRNA sequences represent new species or vari-
ants of established species. Heterogeneity within the 16S
rRNA gene has been described for multiple species, including
M. gordonae [13]. Conversely, among rapid growers, new
species have been described that share identical 16S rRNA
genes but differ in other genetic and biochemical traits
[8,14]. In this respect, rpoB sequences are increasingly used
to deﬁne novel species [14].
What should constitute a new species? A unique 16S
rRNA gene sequence remains the reference standard,
although an exact cut-off point indicating distinct taxa has
not been established for mycobacteria. A separate species
status based entirely on unique 16S rDNA sequences would
result in hundreds, if not thousands, of new species; it is
doubtful whether this would serve clinicians or only add to
the confusion. The results obtained in the present study
demonstrate the presence of a large number of potentially
new species. Moreover, human isolates represent only the
tip of the ‘NTM-iceberg’ [8]. In this respect, we agree with
Telenti [15], who has proposed that ‘clinical meaningfulness
should be the key to taxonomic precision’, although this
should include human and veterinary medicine.
Amidst an ever increasing number of species, a classiﬁca-
tion of NTM based on virulence factors, not unlike Runyon’s
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[16] classiﬁcation based on growth rate and pigmentation,
may be a future strategy. Such a classiﬁcation could begin if
more entire NTM genomes are sequenced [17].
In conclusion, 4% of NTM isolates submitted to our refer-
ence laboratory were unidentiﬁable Mycobacterium species. A
minority was isolated from normally sterile sites or samples
and may comprise causative agents of human disease. Period-
ical re-analysis of UMS is warranted to re-classify them; 2%
remained unidentiﬁable after re-analysis. Identiﬁcation by
reverse line blot assays underestimates the genetic heteroge-
neity among NTM. This heterogeneity can be clinically rele-
vant because speciﬁc (sub)species can cause speciﬁc disease
types. Sequence-based identiﬁcation is preferable, at least at
the reference laboratory level, although adequate targets and
the number of targets needed for clinically useful results
remain to be established. The number of NTM species in the
environment is probably so high that clinical UMS isolates
should be analysed and given a separate species status only if
this is clinically meaningful.
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